Part of the news unfolds in regards to Rusan Pharma Investing 300 Crores in New API Facility in MP’s Pithampur. This news is circulating on the internet and people are trying to collect every detail about the news. The pharmaceutical company Rusan Pharma launched a new plant for active pharmaceutical ingredients. This launch took place on Saturday in Pithampur, Madhya Pradesh. This news is circulating on the Internet and is attracting people’s attention. What happened? What is behind the launch? We will talk about everything in this article. Let’s continue the article.
Rusan Pharma unveils ₹300 crore API manufacturing facility
According to the report, this facility is poised to make 400 metric APIs annually and is expected to create more than 300 jobs. The organization has invested Rs 300 crore in the facility located within the Pithampur Special Economic Zone. The new provision will leverage Rusan Pharma’s existing API capacity, motivating it to supply critical APIs to meet the growing demand for addiction and pain products in India and globally. We will tell you more important details about the news that you will find in the next section of the article.
Based on the report, the Organization is known for increasingly inventive products, such as sublingual buprenorphine and sublingual buprenorphine naloxone tablets, which are used in the treatment of drug abuse, transdermal lidocaine, apomorphine injections, and is also used to treat Parkinson’s disease, buprenorphine, and domestic fentanyl formulations. And not only that, they also make nicotine transdermal patches for quitting smoking. Kunal Saxena, who serves as Managing Director of Rusan Pharma, commented that with an investment of around 300 million rupees in two phases, this new API facility will increase their current API production capacity from 40 metric tonnes at Ankleshwar to 400 metric tonnes tons at Pithampur. Scroll down the page to find out more information about the news.
Furthermore, the company’s statement was released that the current GMP permit for its API finished formulations has the capacity to meet 90 percent of global demand. The company has the approval of several competent authorities, for example the South African Health Products Regulatory Authority, Health Canada, the European Union, the United Arab Emirates and the Therapeutic Products Authority of Australia. If we receive further details, we will notify you first on the same site. Stay tuned for more updates.
Categories: Trends
Source: HIS Education